100 likes | 167 Vues
Women Have Potential Increase in Risk from Smoking.
E N D
Women Have Potential Increase in Risk from Smoking 1. Risch HA, et al. Am J Epidemiol. 1993;138:281. 2. Harris RE, et al. Int J Epidemiol. 1993;22:592. 3. Zang EA, et al. J Natl Cancer Inst. 1996;88:183. 4. Osann KE, et al. Int J Cancer. 1993;22:44. 5. Henschke CI, et al. Lung Cancer. 2004;43:1.
Other Studies Show No Increased Risk for Women Smokers 1. Kreuzer M, et al. Br J Cancer. 2000;82:227-233. 2. Halpern MT, et al. J Natl Cancer Inst. 1993;85:422-423. 3. Bach PB, et al. J Natl Cancer Inst. 2003;95:470-478.
DNA Repair Capacity (DRC) • Bulky DNA lesions from tobacco repaired by nucleotide excision repair pathway • DRC leads to risk of lung cancer1,2 • DRC in people <60 years old, women, those with positive family history • However, DRC may improve response to chemotherapy3 1. Wei Q, et al. J Natl Cancer Inst. 2000; 92:1764. 2. Spitz MR, et al. Cancer Epidemiol Biomarkers Prev. 2003;12:689. 3. Lord RVN, et al. Clin Cancer Res. 2002;8:2286.
CYP1A1 expression significantly correlates with levels of DNA adducts per pack-year smoking history CYP1A1 40 32 24 DNA-Adducts/108 Nucleotides 16 8 r = 0.50P = .009 0 0 300 600 900 1200 CYP1A1/106 GAPDH Mollerup S, et al. Cancer Res. 1999;59:3317.
Survival Differences by Gender in E1594* Improvement in survival remained even when adjusted for performance status, weight loss, brain metastases, and stage. *Patients treated with 1 of 4 platinum doublets. Wakelee HA, et al. J Thorac Oncol. 2006;1:441.
E1594 Toxicity* No difference in leukopenia, thrombocytopenia, anemia, coagulation, infection, diarrhea, stomatitis, hepatitic toxicity, hypertension/hypotension. *Patients treated with 1 of 4 platinum doublets. Wakelee HA, et al. J Thorac Oncol. 2006;1:441.
Survival Differences by Gender in E4599* OS = overall survival; HR = hazard ratio; PFS = progression-free survival; RR = response rate. *Patients treated with carboplatin/paclitaxel/bevacizumab vs carboplatin/paclitaxel. Brahmer J, et al. J Clin Oncol. 2007;24(18S). Abstract 7036.
Gender Differences in E4599 • Higher proportion of women on carboplatin/paclitaxel/bevacizumab compared with paclitaxel/carboplatin with liver involvement (P = .003) and slightly higher proportion with prior weight loss • Higher proportion of women on the carboplatin/paclitaxel/bevacizumab compared with men on the carboplatin/paclitaxel/bevacizumab arm had hypertension (P = .02) • More grade 5 febrile neutropenia experienced by women than by men on carboplatin/paclitaxel/bevacizumab (P = .03) • No differences in % receiving maintenance bevacizumab or 2nd-line treatment Brahmer J, et al. J Clin Oncol. 2007;24(18S). Abstract 7036.
Menopausal Status of Women Affects Survival with Advanced NSCLCCombined Analysis of E1594 and E4599 Confirmed similar results by SWOG, presented at ASCO 20072 1. Wakelee HA, et al. J Thorac Oncol. 2007;2(8 suppl 4).Abstract P1-052. 2. Albain K, et al. J Clin Oncol. 2007;25(18S). Abstract 7549.
K-ras Mutations • Promotes cancer growth in response to estrogen and other hormones • Significant association between female gender and K-ras mutation after adjustment for carcinogen exposure (OR = 3.3) • K-ras mutations in resected lung cancers from female vs male smokers Nelson HH, et al. J Natl Cancer Inst. 1999;91:2032.